AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Bioregulator

    Livagen (20mg)

    Subcutaneous injectionDaily20mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇷🇺 МЗ РФ (Ливаген®)

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Approved by select regulatory agencies — not FDA/EMA
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Free Access

    How It Works

    Livagen binds to specific DNA sequences in hepatocytes, epigenetically regulating the gene expression of proteins involved in liver function, detoxification, and immune response.

    Quick Start

    • Typical dose: 1–2mg subcutaneously
    • Frequency: Daily for 10–20 days
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — Livagen 20mg

    Educational only
    Vial Size— affects syringe units
    BAC Water2 mL
    Concentration10.00 mg/mL

    Route: Subcutaneous injection | Frequency: Daily

    WeekDoseUnits (per injection)
    1–2
    1mg
    10 Units (0.10 mL)
    3+
    2mg
    20 Units (0.20 mL)

    10–20 day cycle, repeat every 3–6 months. Khavinson bioregulator peptides act via epigenetic regulation.

    Related compounds

    Reconstitution Steps

    1. Clean the stoppers with an alcohol wipe.
    2. Draw up 2mL of bacteriostatic water.
    3. Slowly inject into the side wall of the vial.
    4. Gently swirl until fully dissolved.
    5. Store in the refrigerator (2–8°C).

    Protocol Overview

    • Livagen is a liver bioregulator developed by Professor Vladimir Khavinson.
    • It acts via epigenetic regulation of genes related to liver function.
    • It is used in detoxification and liver regeneration protocols.

    Dosing Protocol

    • 1–2mg/day subcutaneously for 10–20 days.
    • Repeat cycle every 3–6 months.
    • Can be combined with other Khavinson bioregulators.
    • Break between cycles: After the cycle (10–20 days), a break of 3–6 months is recommended. Khavinson bioregulator peptides — typically 2–3 cycles/year.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (10–20 days), a break of 3–6 months is recommended. Khavinson bioregulator peptides — typically 2–3 cycles/year.

    Minimum wait period: 12 weeks

    Storage Instructions

    • Reconstituted: 2–8°C, use within 21 days.
    • Powder: 2–8°C.

    Important Notes

    • Bioregulator peptides act cumulatively — results may appear after the cycle is complete.
    • Consult a physician if you have liver disease.
    • Low side effect profile due to its physiological action.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Supports liver function
    • Enhances detoxification
    • Immunomodulation
    • Anti-aging effect on the liver

    Potential Side Effects:

    • Minimal — mild irritation at the injection site
    • Rare: slight fatigue during detoxification

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🫁 Hepatic
    🟡 Moderate / Theoretical

    Hepatic bioregulator — theoretical risk

    Targets hepatocytes via epigenetic regulation. In patients with chronic liver disease, improper regulation could theoretically worsen fibrotic progression.

    📄 Khavinson VK — Bull Exp Biol Med

    References

    1. Khavinson Bioregulators — Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144.
      View Source
    2. Hepatoprotective Peptides — Khavinson VK, Malinin VV. Gerontological aspects of genome peptide regulation. Karger, Basel. 2005.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    1
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇷🇺
    МЗ РФ
    Approved

    Ливаген® · Hepatic bioregulation (2007)

    Approved in Russia (Khavinson bioregulator)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    1 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu